Enliven Therapeutics reaches FDA alignment on relcobatinib (ELVN-001) Phase 3 trial design for previously treated CML

Voyager signs cancer research mission management contract

Pillar Biosciences introduces oncoReveal Myeloid v2 Panel

AbbVie and Genmab report positive results from epcoritamab Phase 3 study in diffuse large B-cell lymphoma

Mozart Therapeutics presents MTX-101 clinical and preclinical data at EASD Annual Meeting

Moberg Pharma reports new Phase 3 analyses on terbinafine activity in onychomycosis

GE HealthCare to acquire SOFIE Biosciences for USD945m

Ractigen Therapeutics reports positive first-in-human data for RAG-18 in Duchenne muscular dystrophy

CSL and Alentis partner for lixudebart development and commercialisation for rare kidney and liver diseases

AnnJi Pharmaceutical's AJ201 advances into pivotal Phase 3 trial for SBMA

Teva reports new ecopipam data showing tic reduction in Tourette syndrome

Johnson & Johnson reports two-year ICOTYDE data showing sustained clearance in high-impact psoriasis

Clear Scientific reports positive CS-1103 Phase 2 Results in removing fentanyl from the Body

Avimer Bio and CNIO publish JACS study on computational design of self‑assembling protein cages

MHRA approves Zepzelca and atezolizumab as first-line maintenance therapy for ES-SCLC in the UK